<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03562988</url>
  </required_header>
  <id_info>
    <org_study_id>ST-7666</org_study_id>
    <nct_id>NCT03562988</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study on Vitamin C in Healthy Adults</brief_title>
  <official_title>A Randomized, Examiner-blind, Comparator-controlled, Cross-over Bioequivalence Study on Vitamin C in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Church &amp; Dwight Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>KGK Science Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Church &amp; Dwight Company, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this exploratory pharmacokinetic research study is to demonstrate that both&#xD;
      caplets and gummies provide an effective dose of ascorbic acid in healthy adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, examiner-blind, cross-over study evaluates the bioequivalence of a gummy&#xD;
      containing vitamin C relative to a caplet comparator product in healthy adults.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">December 22, 2017</completion_date>
  <primary_completion_date type="Actual">December 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Plasma L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 Hours)]</measure>
    <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
    <description>Mean Plasma L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 hours)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Leukocyte L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 Hours)]</measure>
    <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
    <description>Mean Leukocyte L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 hours)] for All Study Participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Plasma L-ascorbic Acid as Cmax</measure>
    <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
    <description>Mean Plasma L-ascorbic Acid as Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Leukocyte L-ascorbic Acid as Cmax</measure>
    <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
    <description>Mean Leukocyte L-ascorbic Acid as Cmax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Plasma Vitamin C Absorption Rate as Tmax</measure>
    <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
    <description>Mean Time of maximum Vitamin C concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Leucocyte Vitamin C Absorption Rate as Tmax</measure>
    <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
    <description>Mean Time of maximum Vitamin C concentration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Dietary Exposure</condition>
  <arm_group>
    <arm_group_label>Vitamin C gummy, Then Vitamin C Caplet</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin C tablet, Then Vitamin C gummy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C gummy</intervention_name>
    <description>vitamin C</description>
    <arm_group_label>Vitamin C gummy, Then Vitamin C Caplet</arm_group_label>
    <arm_group_label>Vitamin C tablet, Then Vitamin C gummy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C tablet</intervention_name>
    <description>vitamin C</description>
    <arm_group_label>Vitamin C gummy, Then Vitamin C Caplet</arm_group_label>
    <arm_group_label>Vitamin C tablet, Then Vitamin C gummy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI 18.5 to 29.9 kg/m2 (+/- 1 kg/m2)&#xD;
&#xD;
          -  Healthy as determined by laboratory results and medical history&#xD;
&#xD;
          -  Maintains current level of physical activity throughout duration of study&#xD;
&#xD;
          -  Does not donate blood for the next 3 months after completing study&#xD;
&#xD;
          -  Avoidance of foods and beverages fortified with vitamin C for at least 7 days prior to&#xD;
             enrollment and duration of study&#xD;
&#xD;
          -  Avoidance of citrus foods, citrus juices, and tomato juice for at least 7 days prior&#xD;
             to enrollment and duration of study&#xD;
&#xD;
          -  Non smoker or ex-smoker &gt; 1 year&#xD;
&#xD;
          -  Has given voluntary, written informed consent to participate in study&#xD;
&#xD;
          -  Agrees to avoid high caffeine and alcohol intake 72 hours prior to in-clinic test days&#xD;
             and during the 24-hour in-clinic test days&#xD;
&#xD;
          -  Females not of child bearing potential, defined as having had a hysterectomy,&#xD;
             oophorectomy, bilateral tubal ligation or are post-menopausal&#xD;
&#xD;
          -  Females of child bearing potential must agree to use a medically approved method of&#xD;
             birth control and have a negative urine pregnancy test result. Acceptable methods&#xD;
             include hormonal contraceptives, double-barrier method, intrauterine devices,&#xD;
             non-heterosexual lifestyle or agrees to use contraception if planning on changing to&#xD;
             heterosexual partner(s) and/or vasectomy of partner&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, breast feeding, or planning to become pregnant during the&#xD;
             trial&#xD;
&#xD;
          -  Duodenal or gastric ulcer, gastritis, hiatus hernia, or GERD within past 3 months&#xD;
&#xD;
          -  History of irritable bowel syndrome and related disorders&#xD;
&#xD;
          -  Significant gastrointestinal disease (includes but not limited to Celiac disease)&#xD;
&#xD;
          -  History of malabsorption&#xD;
&#xD;
          -  Unstable medical conditions as determined by the Qualified Investigator&#xD;
&#xD;
          -  Blood pressure greater than 150/90 mmHg&#xD;
&#xD;
          -  Cancer except skin cancers completely excised with no chemotherapy or radiation&#xD;
             following and with a negative follow up. (Volunteers with cancer in full remission for&#xD;
             more than 4 years after diagnosis are acceptable)&#xD;
&#xD;
          -  Clinically significant abnormal laboratory results at screening&#xD;
&#xD;
          -  Metabolic disease or chronic diseases (ex/ hyperlipidemia, hypertension,&#xD;
             hypercholesterolemia)&#xD;
&#xD;
          -  Type I or Type II diabetes&#xD;
&#xD;
          -  History of kidney stones&#xD;
&#xD;
          -  Use of prescription or over the counter products known to interact with vitamin C&#xD;
             within 72 hours of enrollment and duration of trial such as aspirin and NSAIDs,&#xD;
             aluminum, iron, and proton pump inhibitors&#xD;
&#xD;
          -  Use of acute over the counter medication within 72 hours of test product dosing&#xD;
&#xD;
          -  Use of tobacco products within the last year&#xD;
&#xD;
          -  More than 2 alcoholic drinks per day&#xD;
&#xD;
          -  Drug abuse within 1 year of enrollment&#xD;
&#xD;
          -  Use of medicinal marijuana&#xD;
&#xD;
          -  Immunocompromised individuals such as individuals that have undergone organ&#xD;
             transplantation or individuals diagnosed with HIV&#xD;
&#xD;
          -  Individuals who have planned surgery during the course of the trial&#xD;
&#xD;
          -  St. John's wort in the last 30 days prior to enrollment and duration of study&#xD;
&#xD;
          -  Use of vitamin C, multivitamins containing vitamin C, or foods or beverages fortified&#xD;
             with vitamin C and other natural healthy products containing vitamin C within 7 days&#xD;
             of enrollment and duration of study&#xD;
&#xD;
          -  Consumption of citrus foods, citrus juices, and tomato juice with 7 days of enrollment&#xD;
             and duration of study&#xD;
&#xD;
          -  Use of anticoagulants, barbiturates, tetracycline antibiotics, beta-blockers,&#xD;
             cyclosporine, prednisone, tricyclic antidepressants, diuretics and nitrate medications&#xD;
&#xD;
          -  Use of natural health products/dietary supplements with 7 days of enrollment or&#xD;
             duration of study&#xD;
&#xD;
          -  Current diagnosis and history of blood/bleeding disorders&#xD;
&#xD;
          -  Current diagnosis and history of anemia of any etiology defined as hemoglobin &lt; 145&#xD;
             g/L for males and &lt; 123 g/L for females&#xD;
&#xD;
          -  History of hemoglobinopathies such as sickle cell anemia or thalassemia, sideroblastic&#xD;
             anemia&#xD;
&#xD;
          -  History of hemochromatosis&#xD;
&#xD;
          -  Blood donation in the past 3 months&#xD;
&#xD;
          -  Individuals who plan to donate blood during the study or within 30 days of completing&#xD;
             the study&#xD;
&#xD;
          -  Participation in a clinical research trial within 30 days prior to enrollment&#xD;
&#xD;
          -  Allergy or sensitivity to supplement ingredients or to any food or beverage provided&#xD;
             during the study&#xD;
&#xD;
          -  Individuals who are cognitively impaired and/or who are unable to give informed&#xD;
             consent&#xD;
&#xD;
          -  Any other condition which in the Qualified Investigator's opinion nay adversely affect&#xD;
             an individual's ability to complete the study or its measures or which may pose&#xD;
             significant risk to the individual&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Annahita Ghassemi</last_name>
    <role>Study Director</role>
    <affiliation>Church &amp; Dwight Company, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Church &amp; Dwight Co., Inc.</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>June 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <results_first_submitted>April 19, 2021</results_first_submitted>
  <results_first_submitted_qc>July 27, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2021</results_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Measure Absorption of Vitamin C in Blood</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT03562988/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Cross over study. Participants received each treatment at one of the two treatment visits.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vitamin C Gummy, Then Vitamin C Caplet</title>
          <description>The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period.</description>
        </group>
        <group group_id="P2">
          <title>Vitamin C Tablet, Then Vitamin C Gummy</title>
          <description>The study consisted of two single-day study periods separated by a 7-day washout. At the first study day, a single oral dose of vitamin C caplet (1027.9mg) was orally administered following a 12 hour fasting period. After a 7 day washout period, a single oral dose of vitamin C gummy (1007.2mg) was orally administered following a 12 hour fasting period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Cross over study. Participants randomly received one treatment at one of the two dosing days and the other treatment at the second dosing day.</population>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>All Study Participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Plasma L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 Hours)]</title>
        <description>Mean Plasma L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 hours)]</description>
        <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
        <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C Gummy</title>
            <description>A single oral dose of vitamin C gummy</description>
          </group>
          <group group_id="O2">
            <title>Vitamin C Caplet</title>
            <description>A single oral dose of vitamin C caplet</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 Hours)]</title>
          <description>Mean Plasma L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 hours)]</description>
          <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
          <units>μmol*min/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1114.66" spread="236.81"/>
                    <measurement group_id="O2" value="1149.09" spread="237.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Leukocyte L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 Hours)]</title>
        <description>Mean Leukocyte L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 hours)] for All Study Participants</description>
        <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
        <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C Gummy</title>
            <description>A single oral dose of vitamin C gummy to monitor vitamin C blood levels&#xD;
Vitamin C gummy: vitamin C</description>
          </group>
          <group group_id="O2">
            <title>Vitamin C Tablet</title>
            <description>A single oral dose of vitamin C tablet to monitor vitamin C blood levels&#xD;
vitamin C tablet: vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Leukocyte L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 Hours)]</title>
          <description>Mean Leukocyte L-ascorbic Acid as Total Area Under the Curve [AUC(0-24 hours)] for All Study Participants</description>
          <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
          <units>nmol*min/10^8 leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="273.20" spread="115.70"/>
                    <measurement group_id="O2" value="297.20" spread="105.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Plasma L-ascorbic Acid as Cmax</title>
        <description>Mean Plasma L-ascorbic Acid as Cmax</description>
        <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
        <population>Includes all Participants from treatment day 1, including that those did not participate in treatment day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C Gummy</title>
            <description>A single oral dose of gummy vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C gummy: vitamin C</description>
          </group>
          <group group_id="O2">
            <title>Vitamin C Tablet</title>
            <description>A single oral dose of tablet vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C tablet: vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma L-ascorbic Acid as Cmax</title>
          <description>Mean Plasma L-ascorbic Acid as Cmax</description>
          <population>Includes all Participants from treatment day 1, including that those did not participate in treatment day 2.</population>
          <units>μmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.75" spread="15.74"/>
                    <measurement group_id="O2" value="78.97" spread="20.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Leukocyte L-ascorbic Acid as Cmax</title>
        <description>Mean Leukocyte L-ascorbic Acid as Cmax</description>
        <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
        <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C Gummy</title>
            <description>A single oral dose of gummy vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C gummy: vitamin C</description>
          </group>
          <group group_id="O2">
            <title>Vitamin C Tablet</title>
            <description>A single oral dose of tablet vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C tablet: vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Leukocyte L-ascorbic Acid as Cmax</title>
          <description>Mean Leukocyte L-ascorbic Acid as Cmax</description>
          <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
          <units>nmol/10^8 leukocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.96" spread="18.91"/>
                    <measurement group_id="O2" value="22.74" spread="13.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Plasma Vitamin C Absorption Rate as Tmax</title>
        <description>Mean Time of maximum Vitamin C concentration</description>
        <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
        <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C Gummy</title>
            <description>A single oral dose of gummy vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C gummy: vitamin C</description>
          </group>
          <group group_id="O2">
            <title>Vitamin C Tablet</title>
            <description>A single oral dose of tablet vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C tablet: vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Plasma Vitamin C Absorption Rate as Tmax</title>
          <description>Mean Time of maximum Vitamin C concentration</description>
          <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" spread="0.71"/>
                    <measurement group_id="O2" value="2.88" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Leucocyte Vitamin C Absorption Rate as Tmax</title>
        <description>Mean Time of maximum Vitamin C concentration</description>
        <time_frame>baseline, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12 and 24 hours</time_frame>
        <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
        <group_list>
          <group group_id="O1">
            <title>Vitamin C Gummy</title>
            <description>A single oral dose of gummy vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C gummy: vitamin C</description>
          </group>
          <group group_id="O2">
            <title>Vitamin C Tablet</title>
            <description>A single oral dose of tablet vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C tablet: vitamin C</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Leucocyte Vitamin C Absorption Rate as Tmax</title>
          <description>Mean Time of maximum Vitamin C concentration</description>
          <population>Includes all Participants from treatment day 1, including those did not participate in treatment day 2.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" spread="3.61"/>
                    <measurement group_id="O2" value="4.58" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants entered any AE's in a daily diary from the initiation of the study until 24 hours after the last oral dosing. Additionally, participants were asked about AE's at each visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin C Gummy</title>
          <description>A single oral dose of gummy vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C gummy: vitamin C</description>
        </group>
        <group group_id="E2">
          <title>Vitamin C Tablet</title>
          <description>A single oral dose of tablet vitamin C to monitor vitamin C blood levels&#xD;
Vitamin C tablet: vitamin C</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Neutrophil Count</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Mild Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Confidentiality and Master Service Agreement</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Annahita Ghassemi, PhD</name_or_title>
      <organization>Church &amp; Dwight Co., Inc</organization>
      <phone>609-806-1200</phone>
      <email>annahita.ghassemi@churchdwight.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

